CIK 0001813814 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Definium Therapeutics, Inc.
Sign in to watch- Ticker
- DFTX
- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- 212-220-6633
- Business address
- ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK, NY, 10007
- Former names
- Mind Medicine (MindMed) Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,023,010
- in 6 filings, $3.0M under 10b5-1 plans
Net −$3,023,010. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Barrow Robert −$1.9M Chief Executive Officer sold 2% of stake
- Sullivan Mark −$514K Chief Legal Officer sold 3% of stake
- Karlin Daniel −$397K Chief Medical Officer sold 1% of stake
- Roberts Brandi −$123K Chief Financial Officer sold <1% of stake
- Wiley Matthew T. −$113K Chief Commercial Officer sold <1% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-25 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 | −10,853 | $36.57 | $397K | 792,846 |
| 2026-09-25 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −31,550 | $36.57 | $1.2M | 2,213,090 |
| 2026-09-25 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −3,097 | $36.57 | $113K | 359,036 |
| 2026-09-25 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 | −14,051 | $36.57 | $514K | 494,228 |
| 2026-09-25 | Roberts Brandi Chief Financial Officer | Sale 10b5-1 | −3,377 | $36.57 | $123K | 394,528 |
| 2026-09-18 | Krebs Andreas Director | Option exercise | +1,629 | $35.52 | $58K | 21,402 |
| 2026-09-18 | Krebs Andreas Director | Option exercise · Stock Option (Right to Buy) | −1,629 | 0 | ||
| 2026-09-18 | Vallone Carol A Director | Option exercise | +1,086 | $35.52 | $39K | 22,296 |
| 2026-09-18 | Vallone Carol A Director | Option exercise · Stock Option (Right to Buy) | −1,086 | 0 | ||
| 2026-09-14 | Karlin Daniel Chief Medical Officer | Grant or award | +200,000 | 803,699 | ||
| 2026-09-14 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +125,000 | 362,133 | ||
| 2026-09-14 | Sullivan Mark Chief Legal Officer | Grant or award | +125,000 | 508,279 | ||
| 2026-09-14 | Roberts Brandi Chief Financial Officer | Grant or award | +125,000 | 397,905 | ||
| 2026-09-14 | Barrow Robert Chief Executive Officer | Grant or award | +750,000 | 2,244,640 | ||
| 2026-09-03 | Barrow Robert Chief Executive Officer | Sale 10b5-1 | −19,023 | $37.94 | $722K | 1,494,640 |
| 2026-09-02 | Barrow Robert Chief Executive Officer | Grant or award 10b5-1 | +40,000 | 1,513,663 | ||
| 2026-08-12 | Barrow Robert Chief Executive Officer | Grant or award | +375,000 | 1,473,246 | ||
| 2026-08-12 | Karlin Daniel Chief Medical Officer | Grant or award | +100,000 | 603,282 | ||
| 2026-08-12 | Sullivan Mark Chief Legal Officer | Grant or award | +62,500 | 383,071 | ||
| 2026-08-12 | Wiley Matthew T. Chief Commercial Officer | Grant or award | +62,500 | 237,133 |
Page 1 of 12 · 225 trades